Therapeutic Antibodies – Multimedia

The development of antibodies for diagnostics or therapeutics requires comprehensive characterization of affinity, specificity and mechanism of action. In particular, antibody-drug conjugates (ADCs) are an exciting and emerging class of biopharmaceuticals with applications in cancer.

Biolayer Interferometry (BLI) technology has greatly advanced the process of antibody discovery, and the latest platforms offer reliable, high precision analysis which researchers can rely on.

Affinity purification platforms such as Protein A or L are well-established in the manufacturing process of therapeutic monoclonal antibodies. However, with the development of engineered modalities such as bi-specific antibodies, fragments and Fc-fusion proteins, challenges in the downstream process of these molecules arise.

In recent years, different therapeutic antibody modalities have been developed to address different therapeutic needs.

In this episode of Opinionated Science we dive into the world of therapeutic antibodies with Bio-Rad.

This is especially critical for bispecific antibodies, which are regarded as the second generation of antibody cancer therapies.

In this episode, we speak with Andris Abramenkovs, product manager of CellCelector technology at Sartorius.

In the “Quality by Design” approach for monoclonal antibody (mAb)-based therapeutics development, stability characterization—the probability of a protein unfolding—is performed to ensure that structure and function are preserved throughout development and manufacturing.

In less than 10 minutes, Professor Andrew Zydney covers: What are biopharmaceuticals? How do they differ from traditional small-molecule pharmaceuticals? How are they made? What factors might influence the high cost of biopharmaceuticals?

Speaking at The Landscape of Cancer Research 2021 online symposium, Tianzi Li delivered her talk on the discovery of novel targets and the use of antibodies in cancer therapy.